At 12 weeks, most patients had a reduction in spleen volume.
A single dose of cilta-cel yielded early, deep, and durable responses in heavily pretreated patients with relapsed/refractory multiple myeloma.
Patients with fewer prior lines of therapy in which they were exposed or refractory to alkylators generally had better outcomes.
Researchers sought to determine whether gilteritinib would have efficacy in patients with relapsed/refractory AML who had received prior TKI therapy.
Researchers sought to determine whether tafasitamab with lenalidomide would improve outcomes for patients with relapsed/refractory DLBCL.
Dasatinib produced responses regardless of comorbidity burden.
The combination continued to best CHOP at 5 years.
Researchers sought to determine if there would be a survival benefit with daratumumab combined with lenalidomide and dexamethasone in patients with transplant-ineligible MM.
Researchers sought to identify patients with germline predisposition syndromes without syndromic features using an algorithmic approach compared with classic methods.
Researchers sought to determine whether GVHD prophylaxis with posttransplant cyclophosphamide following allo-HSCT would be associated with a higher risk of infection.
Researchers sought to determine if treatment with PTCy is safe for patients with hematologic malignancies in the HLA-haploidentical setting.
Mutations in JAK2, SF3B1, and IDH2 were associated with indolent disease.
Adding isatuximab to carfilzomib and dexamethasone also improved the depth of response.
Survival outcomes were comparable for patients who received tisagenlecleucel and those who received lisocabtagene maraleucel.
Researchers sought to determine the recommended phase 2 dose, safety, and efficacy of pirtobrutinib in patients with B-cell malignancies.
Researchers sought to determine whether there was an association between NPDs and CAR-T therapy in patients with multiple myeloma.
Researchers found a “strong genetic basis” for racial differences in survival.
The median duration of response was 31.6 months, and the median duration of complete response was not reached.
Researchers sought to determine whether FLAG-IDA with venetoclax would yield MRD-negative composite complete remission in patients with newly diagnosed AML.
After initial triple-class exposure, most patients received a combination of triple-class agents and other agents.